CD4+ T cells migrate from airway to bone marrow after antigen inhalation in rats - 24/08/11
Abstract |
Background |
IL-5–producing T lymphocytes increase in rat bone marrow after inhalational challenge with allergen.
Objective |
To test the hypothesis that T cells migrate from the airways to the marrow, we examined the trafficking of T cells in Brown Norway rats after sensitization and challenge with ovalbumin.
Methods |
Purified CD4+ T cells, harvested from cervical lymph nodes of naive and ovalbumin-sensitized donors, were labeled with carboxy fluorescein diacetate succinimidyl ester; 20 × 106 cells were placed in the trachea of naive or sensitized recipients under anesthesia, and 18 hours later, animals were challenged with inhaled ovalbumin. Cells were harvested 24 hours later from the bone marrow, bronchoalveolar lavage fluid, lungs, the lung blood pool of cells, lung draining lymph nodes, peripheral blood, and spleen.
Results |
The number of carboxy fluorescein diacetate succinimidyl ester–positive cells, measured by fluorescence-activated cell sorter, in the bone marrow of ovalbumin sensitized, primed T-cell recipients was higher than either the sham-sensitized, primed T-cell recipients or sham-sensitized, naive T-cell recipients (P < .05). The number of eosinophils in both bone marrow and bronchoalveolar lavage fluid was increased in ovalbumin-sensitized, primed T-cell recipients. The expression of the T-cell chemoattractants eotaxin and IL-16, evaluated by immunohistochemistry, was higher in the bone marrow of ovalbumin-sensitized, primed T-cell recipients.
Conclusions |
CD4+ T cells travel from airway to bone marrow after antigen inhalation. The homing of the CD4+ T cells might be facilitated by eotaxin and IL-16 expression in the bone marrow and might contribute to the stimulation of eosinophilopoiesis after airway allergen exposure.
Le texte complet de cet article est disponible en PDF.Keywords : T-cell trafficking, CFSE, bone marrow, lung, eotaxin, interleukin-16, eosinophilia
Abbreviations : BAL, BM, CFSE, MBP, MIP, OVA
Plan
| Supported by the Canadian Institutes of Health Research and GlaxoSmith-Kline Canada. |
Vol 113 - N° 3
P. 455-461 - mars 2004 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
